HK1214169A1 - 用於治疗癌症的瑞戈非尼和乙酰水杨酸的组合 - Google Patents
用於治疗癌症的瑞戈非尼和乙酰水杨酸的组合 Download PDFInfo
- Publication number
- HK1214169A1 HK1214169A1 HK16102326.3A HK16102326A HK1214169A1 HK 1214169 A1 HK1214169 A1 HK 1214169A1 HK 16102326 A HK16102326 A HK 16102326A HK 1214169 A1 HK1214169 A1 HK 1214169A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- cancer
- combination
- regorafenib
- acetylsalicylic acid
- limited
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12185852.6 | 2012-09-25 | ||
| EP12185852 | 2012-09-25 | ||
| PCT/EP2013/069735 WO2014048881A1 (en) | 2012-09-25 | 2013-09-23 | Combination of regorafenib and acetylsalicylic acid for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1214169A1 true HK1214169A1 (zh) | 2016-07-22 |
Family
ID=46963566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK16102326.3A HK1214169A1 (zh) | 2012-09-25 | 2013-09-23 | 用於治疗癌症的瑞戈非尼和乙酰水杨酸的组合 |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US10898500B2 (enExample) |
| EP (1) | EP2900269B1 (enExample) |
| JP (1) | JP6294888B2 (enExample) |
| KR (1) | KR102210575B1 (enExample) |
| CN (1) | CN104994876A (enExample) |
| AU (1) | AU2013322854B2 (enExample) |
| BR (1) | BR112015006686B1 (enExample) |
| CA (1) | CA2885688C (enExample) |
| CL (1) | CL2015000744A1 (enExample) |
| CY (1) | CY1120939T1 (enExample) |
| DK (1) | DK2900269T3 (enExample) |
| EA (1) | EA032023B1 (enExample) |
| ES (1) | ES2687985T3 (enExample) |
| HK (1) | HK1214169A1 (enExample) |
| HR (1) | HRP20181462T1 (enExample) |
| HU (1) | HUE039878T2 (enExample) |
| IL (1) | IL237690B (enExample) |
| LT (1) | LT2900269T (enExample) |
| MX (1) | MX357035B (enExample) |
| MY (1) | MY183969A (enExample) |
| NZ (1) | NZ705860A (enExample) |
| PH (1) | PH12015500587A1 (enExample) |
| PL (1) | PL2900269T3 (enExample) |
| PT (1) | PT2900269T (enExample) |
| RS (1) | RS57875B1 (enExample) |
| SG (2) | SG10201702356VA (enExample) |
| SI (1) | SI2900269T1 (enExample) |
| WO (1) | WO2014048881A1 (enExample) |
| ZA (1) | ZA201502840B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2014DN09346A (enExample) | 2012-06-13 | 2015-07-17 | Hoffmann La Roche | |
| MA37940B1 (fr) | 2012-09-25 | 2018-09-28 | Hoffmann La Roche | Derives d'octahydro-cyclopenta(c)pyrrole substitues inhibiteurs de l'autotaxine, utiles pour traiter les affections renales, hepatiques et inflammatoires, les affections du systeme nerveux, les maladies fibreuses. |
| AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
| UA118201C2 (uk) | 2013-11-26 | 2018-12-10 | Ф. Хоффманн-Ля Рош Аг | НОВИЙ ОКТАГІДРОЦИКЛОБУТА[1,2-c;3,4-c']ДИПІРОЛ-2-ІЛ |
| WO2015144609A1 (en) | 2014-03-26 | 2015-10-01 | F. Hoffmann-La Roche Ag | Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors |
| EP3590939A1 (en) | 2014-03-26 | 2020-01-08 | F. Hoffmann-La Roche AG | Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors |
| CN103923001B (zh) * | 2014-04-30 | 2016-02-10 | 药源药物化学（上海）有限公司 | 瑞戈非尼盐及其晶型、制备方法 |
| MA41898A (fr) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
| PE20180479A1 (es) | 2015-09-04 | 2018-03-07 | Hoffmann La Roche | Nuevos derivados de fenoximetilo |
| CN105267167A (zh) * | 2015-09-11 | 2016-01-27 | 江苏嘉逸医药有限公司 | 一种瑞戈非尼口服固体药物组合物的制备方法 |
| CA2984585A1 (en) | 2015-09-24 | 2017-03-30 | F. Hoffmann-La Roche Ag | New bicyclic compounds as dual atx/ca inhibitors |
| MX2018002217A (es) | 2015-09-24 | 2018-03-23 | Hoffmann La Roche | Nuevos compuestos biciclicos como inhibidores de autotaxina (atx). |
| CR20180057A (es) | 2015-09-24 | 2018-04-02 | Hoffmann La Roche | Nuevos compuestos biciclicos como inhibidores duales de atx/ca. |
| PE20180451A1 (es) | 2015-09-24 | 2018-03-05 | Hoffmann La Roche | Nuevos compuestos biciclicos como inhibidores de atx |
| EP3474858B1 (en) * | 2016-06-28 | 2021-08-18 | Asamedic AS | Two-component composition comprising acetylsalicylic acid |
| RU2019132254A (ru) | 2017-03-16 | 2021-04-16 | Ф. Хоффманн-Ля Рош Аг | Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca |
| EP3596060B1 (en) | 2017-03-16 | 2023-09-20 | F. Hoffmann-La Roche AG | New bicyclic compounds as atx inhibitors |
| WO2018219807A1 (en) * | 2017-06-02 | 2018-12-06 | Bayer Aktiengesellschaft | Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer |
| EP3501523A1 (en) | 2017-12-22 | 2019-06-26 | Asamedic AS | Two-component compositions comprising acetyl salicylic acid and a carbonate salt |
| EP3501522A1 (en) | 2017-12-22 | 2019-06-26 | Asamedic AS | Compositions comprising acetylsalicylic acid and a phosphate salt |
| KR20210156389A (ko) | 2020-06-17 | 2021-12-27 | 재단법인대구경북과학기술원 | 레고라페닙을 유효성분으로 포함하는 염증질환의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001002014A1 (en) * | 1999-07-02 | 2001-01-11 | Hisamitsu Pharmaceutical Co., Inc. | Medicinal compositions for treating colorectal cancer |
| US20040121004A1 (en) | 2002-12-20 | 2004-06-24 | Rajneesh Taneja | Dosage forms containing a PPI, NSAID, and buffer |
| NZ544920A (en) * | 2003-07-23 | 2009-11-27 | Bayer Healthcare Llc | 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions |
| KR20080074974A (ko) * | 2005-11-10 | 2008-08-13 | 바이엘 헬스케어 아게 | 당뇨병성 신경병증을 치료하기 위한 디아릴 우레아 |
| AR062927A1 (es) | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
| GB201002530D0 (en) * | 2010-02-15 | 2010-03-31 | Univ Wolverhampton The | Di-aspirin derivatives |
| AR081060A1 (es) | 2010-04-15 | 2012-06-06 | Bayer Schering Pharma Ag | Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida |
-
2013
- 2013-09-23 CA CA2885688A patent/CA2885688C/en active Active
- 2013-09-23 MX MX2015003728A patent/MX357035B/es active IP Right Grant
- 2013-09-23 HK HK16102326.3A patent/HK1214169A1/zh unknown
- 2013-09-23 PT PT13770659T patent/PT2900269T/pt unknown
- 2013-09-23 WO PCT/EP2013/069735 patent/WO2014048881A1/en not_active Ceased
- 2013-09-23 DK DK13770659.4T patent/DK2900269T3/en active
- 2013-09-23 PL PL13770659T patent/PL2900269T3/pl unknown
- 2013-09-23 LT LTEP13770659.4T patent/LT2900269T/lt unknown
- 2013-09-23 AU AU2013322854A patent/AU2013322854B2/en active Active
- 2013-09-23 US US14/431,119 patent/US10898500B2/en active Active
- 2013-09-23 CN CN201380050150.7A patent/CN104994876A/zh active Pending
- 2013-09-23 ES ES13770659.4T patent/ES2687985T3/es active Active
- 2013-09-23 JP JP2015532437A patent/JP6294888B2/ja active Active
- 2013-09-23 HR HRP20181462TT patent/HRP20181462T1/hr unknown
- 2013-09-23 SG SG10201702356VA patent/SG10201702356VA/en unknown
- 2013-09-23 MY MYPI2015700911A patent/MY183969A/en unknown
- 2013-09-23 EP EP13770659.4A patent/EP2900269B1/en active Active
- 2013-09-23 EA EA201500365A patent/EA032023B1/ru not_active IP Right Cessation
- 2013-09-23 HU HUE13770659A patent/HUE039878T2/hu unknown
- 2013-09-23 SI SI201331181T patent/SI2900269T1/sl unknown
- 2013-09-23 RS RS20181015A patent/RS57875B1/sr unknown
- 2013-09-23 NZ NZ705860A patent/NZ705860A/en unknown
- 2013-09-23 KR KR1020157010519A patent/KR102210575B1/ko active Active
- 2013-09-23 SG SG11201501963RA patent/SG11201501963RA/en unknown
- 2013-09-23 BR BR112015006686-0A patent/BR112015006686B1/pt active IP Right Grant
-
2015
- 2015-03-12 IL IL237690A patent/IL237690B/en active IP Right Grant
- 2015-03-17 PH PH12015500587A patent/PH12015500587A1/en unknown
- 2015-03-24 CL CL2015000744A patent/CL2015000744A1/es unknown
- 2015-04-24 ZA ZA2015/02840A patent/ZA201502840B/en unknown
-
2018
- 2018-09-20 CY CY181100976T patent/CY1120939T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6294888B2 (ja) | 癌を治療するためのレゴラフェニブおよびアセチルサリチル酸の組み合わせ | |
| JP7475402B2 (ja) | 癌治療のためのレゴラフェニブとｐｄ－１／ｐｄ－ｌ１（２）阻害剤の併用 | |
| RU2774838C2 (ru) | Комбинация регорафениба и ингибиторов pd-1/pd-l1(2) для лечения рака | |
| HK40015063A (en) | Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer | |
| WO2021160708A1 (en) | Combination of regorafenib and msln-ttc for treating cancer |